Table 5 Cox Proportional hazards regression model demonstrating that reaching the initial target trough in <5 days is associated with improved study outcome measures
From: Optimization of time to initial vancomycin target trough improves clinical outcomes
Outcome | Hazard Ratio (95% CI) | P value |
|---|---|---|
Inpatient length of staya | ||
Time to target trough | ||
<5 vs. ≥5 days | 2.52 (1.54–4.14) | <0.001 |
1–<2 vs. ≥5 days | 1.97 (1.09–3.56) | 0.024 |
2–<3 vs. ≥5 days | 2.3 (1.35–3.92) | 0.002 |
3–<4 vs. ≥5 days | 2.13 (1.27–3.56) | 0.004 |
Time to clinical stabilitya | ||
Time to target trough | ||
<5 vs. ≥5 days | 2.13 (1.16–3.93) | 0.015 |
1–<2 vs. ≥5 days | 1.51 (0.75–3.04) | 0.243 |
2–<3 vs. ≥5 days | 1.09 (0.56–2.13) | 0.791 |
3–<4 vs. ≥5 days | 1.41 (0.76–2.62) | 0.276 |
Inpatient length of VAN treatmenta | ||
Time to target trough | ||
<5 days vs. ≥5 days | 2.95 (1.8–4.82) | <0.001 |
1–<2 vs. ≥5 days | 3.44 (1.86–6.35) | <0.001 |
2– < 3 vs. ≥5 days | 2.18 (1.27–3.74) | 0.005 |
3– < 4 vs. ≥5 days | 4.67 (2.68–8.14) | <0.001 |
Time to normal white blood cell counta | ||
Time to target trough: | ||
<5 days vs. ≥5 days | 2.08 (1.06–4.08) | 0.034 |
1–<2 vs. ≥5 days | 2.12 (0.86–5.21) | 0.1 |
2–<3 vs. ≥5 days | 1.26 (0.57–2.77) | 0.565 |
3–<4 vs. ≥5 days | 1.72 (0.84–3.53) | 0.138 |